Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antyra, a biotechnology company, has entered into a global licensing agreement with Novo Nordisk, a healthcare company, for IGF-related antagonists for the treatment of cancer and other diseases.
Subscribe to our email newsletter
Under the agreement, Antyra will obtain exclusive rights to develop and commercialize certain IGF antagonists discovered during the research and license collaboration agreement entered into between the companies in December 2001.
IGF, or insulin-like growth factor, is a natural growth promoting entity, the blockage of whose action has attracted attention as a potential anticancer therapy for the treatment of many solid tumors. Financial terms of the agreement were not disclosed.
Neil Goldstein, president and chief scientific officer of Antyra, said: “We are very happy to conclude this arrangement with Novo Nordisk. We believe that the company has generated some exciting data with several of the IGF-1R antagonists and they represent a novel and potentially effective clinical strategy for the treatment of pancreatic and other cancers.”